Related Experiment Video

Updated: Jul 5, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM

Laura Fontana1, Micol E Fiori, Sonia Albini

  • 1Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy. lfontana@iss.it

Plos One
|May 22, 2008
PubMed

Insights

A new study reveals MYCN drives neuroblastoma by activating the miR-17-5p-92 cluster, inhibiting tumor suppressors. Antagomir-17-5p treatment effectively halts neuroblastoma growth by restoring these suppressors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Neuroblastoma is a pediatric cancer often driven by MYCN.
  • The miR-17-5p-92 cluster is implicated in cancer progression.
  • p21 and BIM are key regulators of cell cycle and apoptosis.

Purpose of the Study:

  • To elucidate the role of the MYCN-miR-17-5p-92 axis in neuroblastoma.
  • To investigate antagomir-17-5p as a potential therapeutic strategy.

Main Methods:

  • Analysis of MYCN, miR-17-5p-92 cluster, p21, and BIM expression in neuroblastoma.
  • In vitro and in vivo studies using neuroblastoma cell lines and xenografts.
  • Treatment with antagomir-17-5p.

Main Results:

  • MYCN upregulates the miR-17-5p-92 cluster, which suppresses p21 and BIM.
  • Overexpression of miR-17-5p-92 enhances neuroblastoma tumorigenesis.
  • Antagomir-17-5p treatment inhibited tumor growth by upregulating p21 and BIM, inducing cell cycle arrest and apoptosis.
  • Elevated miR-17-5p and reduced p21 correlate with poor prognosis in MYCN-amplified neuroblastoma.

Conclusions:

  • The MYCN-miR-17-5p-92 pathway is crucial for neuroblastoma progression.
  • Antagomir-17-5p demonstrates therapeutic potential against therapy-resistant neuroblastoma.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...